Disc Medicine (IRON) Competitors $56.27 -1.47 (-2.55%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$56.26 -0.01 (-0.01%) As of 07/15/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IRON vs. ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, NUVL, LNTH, TLX, and AXSMShould you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Disc Medicine vs. Its Competitors Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent Lantheus Telix Pharmaceuticals Axsome Therapeutics Roivant Sciences (NASDAQ:ROIV) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment. Is ROIV or IRON more profitable? Disc Medicine has a net margin of 0.00% compared to Roivant Sciences' net margin of -225.71%. Roivant Sciences' return on equity of -14.76% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-225.71% -14.76% -13.69% Disc Medicine N/A -22.61%-21.07% Which has stronger earnings and valuation, ROIV or IRON? Disc Medicine has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$29.05M265.84-$171.98M-$0.25-45.44Disc MedicineN/AN/A-$109.36M-$3.92-14.35 Do insiders & institutionals hold more shares of ROIV or IRON? 64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by company insiders. Comparatively, 4.2% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media prefer ROIV or IRON? In the previous week, Disc Medicine had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Disc Medicine and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.09 beat Disc Medicine's score of 0.62 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ROIV or IRON? Roivant Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Do analysts recommend ROIV or IRON? Roivant Sciences presently has a consensus target price of $16.50, indicating a potential upside of 45.25%. Disc Medicine has a consensus target price of $96.70, indicating a potential upside of 71.85%. Given Disc Medicine's higher probable upside, analysts clearly believe Disc Medicine is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 SummaryRoivant Sciences beats Disc Medicine on 9 of the 16 factors compared between the two stocks. Get Disc Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRON vs. The Competition Export to ExcelMetricDisc MedicineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.00B$2.96B$5.62B$9.29BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-14.3520.2228.5719.58Price / SalesN/A290.24423.3293.40Price / CashN/A43.1536.0257.93Price / Book3.797.568.135.54Net Income-$109.36M-$55.11M$3.24B$257.73M7 Day Performance0.73%3.81%0.16%-0.08%1 Month Performance8.17%11.60%5.95%8.09%1 Year Performance17.42%-2.11%26.09%13.02% Disc Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRONDisc Medicine3.1997 of 5 stars$56.27-2.5%$96.70+71.9%+14.3%$2.00BN/A-14.3530Insider TradeROIVRoivant Sciences2.79 of 5 stars$10.74-2.3%$17.50+62.9%-1.2%$7.47B$29.05M-42.96860ELANElanco Animal Health1.4887 of 5 stars$14.48-1.1%$15.33+5.9%+9.4%$7.27B$4.44B19.579,000RVMDRevolution Medicines4.5977 of 5 stars$36.67-3.2%$68.00+85.4%-17.8%$7.05B$11.58M-9.17250Analyst ForecastLEGNLegend Biotech3.3666 of 5 stars$35.87+0.6%$72.60+102.4%-26.7%$6.55B$627.24M-60.802,609GRFSGrifols3.5131 of 5 stars$8.87-2.3%$10.30+16.1%+19.7%$6.24B$7.81B7.5823,822News CoverageGap UpTGTXTG Therapeutics3.6158 of 5 stars$35.98-2.0%$40.80+13.4%+78.5%$5.83B$329M149.92290Positive NewsNUVLNuvalent3.2988 of 5 stars$77.93-3.2%$119.60+53.5%+1.8%$5.78BN/A-17.7540LNTHLantheus4.5541 of 5 stars$79.19-1.5%$130.50+64.8%-34.0%$5.56B$1.53B22.50700Positive NewsTLXTelix PharmaceuticalsN/A$15.48-3.7%$22.33+44.3%N/A$5.44B$516.72M0.00N/AAXSMAxsome Therapeutics4.6921 of 5 stars$107.50+2.0%$172.33+60.3%+33.0%$5.19B$385.69M-18.63380Positive NewsAnalyst Revision Related Companies and Tools Related Companies Roivant Sciences Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives Grifols Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Lantheus Alternatives Telix Pharmaceuticals Alternatives Axsome Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRON) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IRON Stock Alerts